The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Adverse events will be closely watched when full data are reported.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
